UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000004213
Receipt No. R000005062
Scientific Title A phase II study of HLA matched related bone marrow or peripheral blood stem cell transplantation for elderly patients with hematologic malignancies using fludarabine and intravenous busulfan.
Date of disclosure of the study information 2010/09/15
Last modified on 2018/03/21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A phase II study of HLA matched related bone marrow or peripheral blood stem cell transplantation for elderly patients with hematologic malignancies using fludarabine and intravenous busulfan.
Acronym JSCT-FB10 PB/BM
Scientific Title A phase II study of HLA matched related bone marrow or peripheral blood stem cell transplantation for elderly patients with hematologic malignancies using fludarabine and intravenous busulfan.
Scientific Title:Acronym JSCT-FB10 PB/BM
Region
Japan

Condition
Condition AML,MDS
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To investigate efficacy of HLA matched related bone marrow or peripheral blood stem cell transplantation using 180mg/m2 of fludarabine and 12.8mg/kg of intravenous busulfan for elderly patients aged 55-70 with AML or MDS.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Event-free survival at 1 year after transplantation
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Conditioning regimen:
Flu 180mg/m2 + ivBu 12.8mg/kg +- TBI 2Gy

GVHD prophylaxis:
HLA matched related BM or PBSC donor
cyclosporine A(CsA) + short-term
methotrexate(MTX)(day 1: 10mg/m2, day 3, 6: 7mg/ m2)
HLA mismatched related BM or PBSC donor and unrelated BM donor
tacrolimus + short-term MTX(day 1: 10mg/m2, day 3, 6, 11: 7mg/m2, administation of MTX on day11 may be omitted by each physician's decision.)
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
55 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria 1.Patients diagnosed as AML or MDS who meet the following conditions,
(a)Patients with AML(except M3)who are in advanced stage beyond first complete remission, are in high risk disease category according to SWOG/ECOG criteria, received more than one course of chemotherapy to achieve complete remission, AML/MLD in first remission, or AML with prior history of myelodysplastic syndrome
(B)Patients with MDS who are in poor prognosis group with high or very high score according to WHO classification-based prognostic scoring system, or required platelet transfusions of at least 10 units/week or red cell transfusions of at least 2 units/month.
2.Age:55-70
3.Those who have available donors(HLA-identical or 1 antigen-mismatched related BM/PBSC, HLA-matched or 1 DR antigen-mismatched unrelated BM
5.Those who have no severe organ dysfunction (T. Bil<2.0mg/dL, AST<=3 X upper limit of normal,ALT<=3 X upper limit of normal, Cr<2.0mg/dl, EF>50%, SpO2>95%)
6.Those who give written informed consent following sufficient explanation.
7.Those who are evaluated to be able to survive more than 3 months.
Key exclusion criteria 1.Those who are positive for anti-HIV antibody
2.Those who have history of gemtuzumab ozogamicin (MylotargTM) use within 4 months
3.Those who have coinciding active malignancies
4.Those who have uncontrolled psychiatric disorder
5.Those who have active infection
6.Those who have prior hematopoietic stem cell transplantation
7.Those who have history of chemotherapy within 30 days before transplant (except hydroxycarbamide or cytarabine therapy for blast control)
8.Those who have hypersensitivity to drugs included in this protocol therapy
9.Those who are considered as inappropriate to register by attending physicians.
Target sample size 42

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Toshihiro Miyamoto
Organization Kyushu Univ. Hospital
Division name Department of Hematology
Zip code
Address Fukuoka, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization JSCT
Division name FB10 datacenter
Zip code
Address
TEL
Homepage URL
Email jsct-office@umin.ac.jp

Sponsor
Institute Japan Study Group for Cell Therapy and Transplantation
Institute
Department

Funding Source
Organization Resarch Foundation for Community Medicine
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2010 Year 09 Month 15 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
142 elderly patients (88 men and 54 women; median age, 61 years; range, 55-70 years) were participated, 103 AML and 39 MDS.  21 received related bone marrow (BM) or peripheral blood (PB), 50 did unrelated BM, and 71 did cord blood (CB).  105 (74%) experienced grade III or greater toxicities including 4 SOS.  Neutrophil engraftment was achieved in 70 out of 71 related BM/PB or unrelated BM recipients, and 61 of 71 UCB recipients.  Cumulative incidences of relapse and non-relapse mortality after 2 years were 24 % and 24.1%, respectively.  Overall and event-free survivals at 2 years were 53.3% and 47.4 %, respectively.  2-year OS was 61.5% in related BM/PB, 67.8% in UBM, and 40.8% in CB recipients, showing inferior OS in CB recipients to the other donor types (P<0.05).  However, for those in good performance status (ECOG 0) and had low blast count in BM (<5%), the differences became not significant (2-year OS were 77.3% in related BM/PB, 68.4% in UBM, and 65.0% in CB recipients). 
Conclusion: The myeloablative dose of ivBu was well tolerated without increased toxicity-related mortality.  The differences between CB and the others could likely be due to relatively poor conditions of CB recipients.  This trial was registered as #UMIN000002426, #UMIN000004213, and #UMIN000004211. 
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2010 Year 09 Month 01 Day
Date of IRB
Anticipated trial start date
2010 Year 09 Month 10 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2010 Year 09 Month 15 Day
Last modified on
2018 Year 03 Month 21 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005062

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.